Skip Navigation



NDT Advance Access published online on April 18, 2008

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn204
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/9/2777    most recent
gfn204v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nielsen, F. T.
Right arrow Articles by Bie, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nielsen, F. T.
Right arrow Articles by Bie, P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats

Finn Thomsen Nielsen1,2, Boye L. Jensen1, Niels Marcussen3, Ole Skøtt1 and Peter Bie1

1 Institute of Physiology and Pharmacology, University of Southern Denmark 2 Department of Nephrology, Odense University Hospital 3 Institute of Pathology, University of Southern Denmark, Odense, Denmark

Correspondence and offprint requests to: Finn Thomsen Nielsen, Institute of Physiology and Pharmacology, University of Southern Denmark, Winsløwparken 21, 3, DK-5000 Odense C, Denmark. Tel: +45-2443-4346; Fax: +45-6541-3452; E-mail: ftn{at}dadlnet.dk



  Abstract

Background. Recent data indicate that aldosterone aggravates cyclosporin A (CsA)-induced nephrotoxicity. We examined whether the mineralocorticoid receptor (MR) blocker eplerenone (EPL) antagonized early deterioration of renal function and blood pressure (BP) increase in CsA-treated rats.

Methods. Male Sprague-Dawley rats received CsA (15 mg/kg/day i.p.) and/or EPL (100 mg/kg/day p.o.) for 21 days. After 2 weeks, arterial, venous and urinary bladder catheters were implanted and the rats were trained to accept a restraining device allowing arterial blood sampling and direct measurement of BP and renal function. BP was measured on-line in conscious rats.

Results. CsA significantly increased systolic BP: 139 ± 4 versus 134 ± 2 mmHg, reduced body weight gain: –5 ± 6 versus 36 ± 7 g, glomerular filtration rate (GFR): 1.02 ± 0.16 versus 2.64 ± 0.27 ml/min, renal blood flow (RBF): 5.3 ± 2.4 versus 13.5 ± 2.1 ml/min and lithium clearance (CLi+): 0.16 ± 0.04 versus 0.26 ± 0.07 ml/min compared to controls. These changes were prevented by simultaneous EPL treatment: systolic BP, 130 ± 4 mmHg; weight gain, 53 ± 7 g; GFR, 1.67 ± 0.26 ml/min; RBF, 12.3 ± 2.1 ml/min and CLi+, 0.27 ± 0.03 ml/min. Analysis of kidney morphology after the CsA treatment showed hyaline vacuolization in tubules and vascular depositions in arterioles; these changes were less pronounced after combination therapy. No significant changes were seen regarding haemoglobin, haematocrit, plasma renin and vasopressin, plasma and urinary sodium, potassium, or osmolality.

Conclusions. MR blockade by EPL prevented short-term alterations in GFR, RBF and hypertension associated with CsA nephrotoxicity. We conclude that the aldosterone-MR pathway contributes markedly to the renal toxicity induced by this calcineurin inhibitor.

Keywords: cyclosporin A; eplerenone; glomerular filtration rate; mineralocorticoid receptor antagonist; nephrotoxicity

Received for publication: 8. 6.07
Accepted in revised form: 19. 3.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.